Axogen, Inc.·4

Jun 26, 4:52 PM ET

Wendell Amy McBride 4

4 · Axogen, Inc. · Filed Jun 26, 2026

Research Summary

AI-generated summary of this filing

Updated

Axogen (AXGN) Director Wendell McBride Receives 4,392 RSUs

What Happened
Wendell Amy McBride, a director of Axogen, Inc. (AXGN), was granted 4,392 restricted stock units (RSUs) on June 24, 2026. The Form 4 reports these as a derivative award at $0 per share (i.e., a grant of contingent units). The grant was valued at approximately $185,000 and vests on June 24, 2027. This is an equity compensation award (routine director grant), not an open-market purchase or sale.

Key Details

  • Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (two days after the grant).
  • Award: 4,392 RSUs granted, reported at $0.00 per unit on the Form 4 (derivative grant).
  • Reported grant valuation: ~$185,000 (per company valuation used to determine award size).
  • Vesting: 1-year cliff — vests on June 24, 2027.
  • Shares owned after transaction: not specified in the provided filing details.
  • Footnotes: F1 — each RSU represents a contingent right to receive one share of common stock; F2 — this is the annual equity grant for Board service based on a $185,000 valuation.
  • Filing timeliness: Form filed two days after the transaction date (appears to meet the standard 2-business-day Form 4 deadline).

Context
RSU grants to directors are common as compensation for board service and should be viewed as routine corporate compensation rather than a direct trading signal. Because these are restricted units (derivative awards), no cash changed hands and the units will convert to shares only if and when they vest.

Insider Transaction Report

Form 4
Period: 2026-06-24
Transactions
  • Award

    Restricted Stock Units

    [F1][F2]
    2026-06-24+4,3924,392 total
    Common Stock (4,392 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
  • [F2]Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.
Signature
/s/ Marc Began, as attorney-in-fact for Amy McBride-Wendell|2026-06-26

Documents

1 file
  • 4
    wk-form4_1782507140.xmlPrimary

    FORM 4